keyword
https://read.qxmd.com/read/38536173/patient-reported-adverse-events-and-early-treatment-discontinuation-among-patients-with-multiple-myeloma
#1
JOURNAL ARTICLE
John Devin Peipert, Fengmin Zhao, Ju-Whei Lee, Shu-En Shen, Edward Ip, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Pamela J Raper, Matthias Weiss, Shaji K Kumar, S Vincent Rajkumar, David Cella, Robert Gray, Lynne I Wagner
IMPORTANCE: There is substantial interest in capturing cancer treatment tolerability from the patient's perspective using patient-reported outcomes (PROs). OBJECTIVE: To examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events. DESIGN, SETTING, AND PARTICIPANTS: This prospective survey study was conducted from February to April 2023...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38523673/the-role-of-proteasomes-in-tumorigenesis
#2
REVIEW
Xiangyi Zhou, Ruqing Xu, Yue Wu, Li Zhou, Tingxiu Xiang
Protein homeostasis is the basis of normal life activities, and the proteasome family plays an extremely important function in this process. The proteasome 20S is a concentric circle structure with two α rings and two β rings overlapped. The proteasome 20S can perform both ATP-dependent and non-ATP-dependent ubiquitination proteasome degradation by binding to various subunits (such as 19S, 11S, and 200 PA), which is performed by its active subunit β1, β2, and β5. The proteasome can degrade misfolded, excess proteins to maintain homeostasis...
July 2024: Genes & Diseases
https://read.qxmd.com/read/38519476/once-weekly-versus-twice-weekly-bortezomib-in-newly-diagnosed-multiple-myeloma-a-real-world-analysis
#3
JOURNAL ARTICLE
Fieke W Hoff, Rahul Banerjee, Adeel M Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D Anderson, Andrew J Cowan, S Vincent Rajkumar, Gurbakhash Kaur
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib. We aimed to analyze the real-world prevalence and efficacy of once-weekly versus twice-weekly bortezomib regimens in newly diagnosed MM. We analyzed 2497 US patients aged 18-70 years treated with commercial first-line bortezomib using nationwide Flatiron Health electronic health record-derived data, including 910 (36...
March 22, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38504552/post-hoc-analysis-of-daratumumab-plus-lenalidomide-bortezomib-and-dexamethasone-in-black-patients-from-final-data-of-the-griffin-study
#4
JOURNAL ARTICLE
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul G Richardson
Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events...
March 19, 2024: British Journal of Haematology
https://read.qxmd.com/read/38500772/factors-determining-the-sensitivity-to-proteasome-inhibitors-of-multiple-myeloma-cells
#5
REVIEW
Marta Pelon, Patryk Krzeminski, Zuzanna Tracz-Gaszewska, Irena Misiewicz-Krzeminska
Multiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins. The high rate of synthesis makes myeloma cells dependent on protein processing mechanisms related to the proteasome. This dependence made proteasome inhibitors such as bortezomib and carfilzomib one of the most important classes of drugs used in multiple myeloma treatment. Inhibition of the proteasome is associated with alteration of a number of important biological processes leading, in consequence, to inhibition of angiogenesis...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38498976/autologous-hsct-with-novel-agent-based-induction-and-consolidation-followed-by-lenalidomide-maintenance-for-untreated-multiple-myeloma
#6
JOURNAL ARTICLE
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto
Triplet regimen comprising proteasome inhibitors, immunomodulatory drugs, and dexamethasone (DEX) is a recommended induction/consolidation therapy for multiple myeloma (MM) patients eligible for transplant. In this Japanese phase II study conducted from 2017 to 2019, newly diagnosed MM patients aged 20-65 received four induction cycles with bortezomib (Bor), lenalidomide (Len), and DEX (VRD), followed by Bor and high-dose melphalan with autologous stem cell rescue. Subsequently, they underwent four consolidation cycles with carfilzomib, Len, and DEX (KRD), followed by Len maintenance until disease progression...
March 18, 2024: Cancer Science
https://read.qxmd.com/read/38494542/adjusted-indirect-treatment-comparison-of-progression-free-survival-with-d-rd-and-vrd-based-on-maia-and-swog-s0777-individual-patient-level-data
#7
JOURNAL ARTICLE
Brian G M Durie, Shaji K Kumar, Eric M Ammann, Alex Z Fu, Shuchita Kaila, Annette Lam, Saad Z Usmani, Thierry Facon
INTRODUCTION: Daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) are commonly used treatment combinations for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). D-Rd and VRd demonstrated superior efficacy relative to lenalidomide and dexamethasone (Rd) in the MAIA and SWOG S0777 trials, respectively, but have not been compared directly in a head-to-head trial. Naïve comparisons of efficacy across the two trials may be biased because MAIA enrolled only TIE patients (median age 73 years), whereas SWOG S0777 enrolled both TIE patients and transplant-eligible patients who chose to defer/refuse frontline stem cell transplantation (median age 63 years)...
March 18, 2024: Advances in Therapy
https://read.qxmd.com/read/38488702/thromboembolic-risk-of-carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma-a-comparative-systematic-review-and-meta-analysis
#8
JOURNAL ARTICLE
Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
Thrombosis represents a frequent and potentially severe complication in individuals diagnosed with multiple myeloma (MM). These events can be driven by both the disease as well as the therapies themselves. Overall, available evidence is inconclusive about the differential thrombogenicity of carfilzomib/lenalidomide/dexamethasone (KRd) and bortezomib/lenalidomide/dexamethasone (VRd). This meta-analysis compares the risk for venous thromboembolism (VTE; including deep venous thrombosis and pulmonary embolism) and arterial thromboembolism (ATE; including myocardial infarction and ischemic stroke) with KRd versus VRd as primary therapy for newly diagnosed MM (NDMM)...
March 15, 2024: American Journal of Hematology
https://read.qxmd.com/read/38485811/real-world-incidence-and-risk-factors-of-bortezomib-related-cardiovascular-adverse-events-in-patients-with-multiple-myeloma
#9
JOURNAL ARTICLE
Bitna Jang, Jonghyun Jeong, Kyu-Nam Heo, Youngil Koh, Ju-Yeun Lee
BACKGROUND: Although most studies on the cardiovascular toxicity of proteasome inhibitors have focused on carfilzomib, the risk of cardiotoxicity associated with bortezomib remains controversial. This study aimed to evaluate the incidence and risk factors of cardiovascular adverse events (CVAEs) associated with bortezomib in patients with multiple myeloma in a real-world setting. METHODS: This cross-sectional study included patients who were treated with bortezomib at a tertiary hospital in South Korea...
February 19, 2024: Blood Research
https://read.qxmd.com/read/38483213/phase-1-study-of-bortezomib-fludarabine-and-melphalan-with-or-without-total-marrow-irradiation-as-allogeneic-hematopoietic-stem-cell-transplant-conditioning-for-high-risk-or-relapsed-refractory-multiple-myeloma
#10
JOURNAL ARTICLE
Colton Ladbury, James Sanchez, Arnab Chowdhury, Joycelynne Palmer, An Liu, Anthony Stein, Myo Htut, Leonardo Farol, Ji-Lian Cai, George Somlo, Michael Rosenzweig, Jeffrey C Wong, Firoozeh Sahebi
OBJECTIVES: We conducted a phase 1 study of a conditioning regimen with or without total marrow irradiation (TMI) before allogeneic hematopoietic stem cell transplantation for patients with high-risk or refractory multiple myeloma. METHODS: Eighteen patients were enrolled on one of 2 strata. Patients with no prior radiation received TMI (900 cGy), fludarabine (FLU), and melphalan (MEL) conditioning, with bortezomib added in the second cohort (stratum I). Patients with prior radiation received FLU, MEL, and bortezomib, without TMI (stratum II)...
March 14, 2024: American Journal of Clinical Oncology
https://read.qxmd.com/read/38480852/treatment-pattern-and-outcomes-of-re-induction-therapy-prior-to-stem-cell-transplantation-in-patients-with-relapsed-refractory-multiple-myeloma-in-germany
#11
JOURNAL ARTICLE
Sandra Sauer, Monika Engelhardt, Karolin Trautmann-Grill, Christoph Kimmich, Mathias Hänel, Martin Schmidt-Hieber, Hans Salwender, Carmen Flossmann, Hiltrud Heckmann, Franziska Ertel, Andrea Friederich, Sachin Patel, Barbara Thun, Marc S Raab
There are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany who received re-induction therapy in second line (78%; n = 134) or third line (22%; n = 37) prior to re-SCT. Index therapy was defined as first completed re-induction therapy for planned myeloablative conditioning and SCT in second/third line within the eligibility period (1/2016-12/2019)...
March 14, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38479337/expression-of-the-chemokine-receptor-ccr1-decreases-sensitivity-to-bortezomib-in-multiple-myeloma-cell-lines
#12
JOURNAL ARTICLE
Mara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, Vasilios Panagopoulos, Craig T Wallington-Gates, Andrew Spencer, Sandra M Dold, Monika Engelhardt, Kate Vandyke, Andrew C W Zannettino
BACKGROUND: The proteasome inhibitor bortezomib is one of the primary therapies used for the haematological malignancy multiple myeloma (MM). However, intrinsic or acquired resistance to bortezomib, via mechanisms that are not fully elucidated, is a barrier to successful treatment in many patients. Our previous studies have shown that elevated expression of the chemokine receptor CCR1 in MM plasma cells in newly diagnosed MM patients is associated with poor prognosis. Here, we hypothesised that the poor prognosis conferred by CCR1 expression is, in part, due to a CCR1-mediated decrease in MM plasma cell sensitivity to bortezomib...
March 7, 2024: Leukemia Research
https://read.qxmd.com/read/38467180/targeting-parp14-with-lomitapide-suppresses-drug-resistance-through-the-activation-of-drp1-induced-mitophagy-in-multiple-myeloma
#13
JOURNAL ARTICLE
Honghao Zhang, Hao Wang, Yuxing Hu, Yang Gao, Jianyu Chen, Yabo Meng, Yingqi Qiu, Rong Hu, Peiyun Liao, Meifang Li, Yanjie He, Zhao Liang, Xiaoling Xie, Yuhua Li
Multiple myeloma (MM) is a hematological malignancy that remains incurable, primarily due to the high likelihood of relapse or development of resistance to current treatments. To explore and discover new medications capable of overcoming drug resistance in MM, we conducted cell viability inhibition screens of 1504 FDA-approved drugs. Lomitapide, a cholesterol-lowering agent, was found to exhibit effective inhibition on bortezomib-resistant MM cells in vitro and in vivo. Our data also indicated that lomitapide decreases the permeability of the mitochondrial outer membrane and induces mitochondrial dysfunction in MM cells...
March 9, 2024: Cancer Letters
https://read.qxmd.com/read/38467118/therapeutic-effect-and-adverse-event-rate-of-different-treatment-methods-in-patients-with-multiple-myeloma-and-renal-insufficiency
#14
JOURNAL ARTICLE
Lijuan Cui, Jing Ning, Rui Yang, Hainan Wang
INTRODUCTION: This study involves the collation and analysis of clinical characteristics and laboratory findings in patients with multiple myeloma (MM) combined with renal insufficiency. The objective was to assess the impact of various treatment methods on patient outcomes and the incidence of adverse events in individuals with MM and renal insufficiency. METHODS: We analyzed the correlation between clinical characteristics, gene loci, fluorescence in situ hybridization, treatment methods, and prognosis in patients with MM and renal insufficiency...
March 11, 2024: International Archives of Allergy and Immunology
https://read.qxmd.com/read/38462771/identification-of-coq2-as-a-regulator-of-proliferation-and-lipid-peroxidation-through-genome-scale-crispr-cas9-screening-in-myeloma-cells
#15
JOURNAL ARTICLE
Miao Li, Chang-Lin Zhang, Di-Sheng Zhou, Sze-Hoi Chan, Xue-Qi Liu, Shu-Na Chen, Zi-Yi Yang, Fei-Er Ju, Xiao-Yan Sang, Zi-Xuan Liu, Qiao-Xia Zhang, Yu-Ming Pan, Si-Si Deng, Xiao-Mei Wang, Li Zhong, Xing-Ding Zhang, Xin Du
Multiple myeloma (MM) is the second most common malignant haematological disease with a poor prognosis. The limit therapeutic progress has been made in MM patients with cancer relapse, necessitating deeper research into the molecular mechanisms underlying its occurrence and development. A genome-wide CRISPR-Cas9 loss-of-function screening was utilized to identify potential therapeutic targets in our research. We revealed that COQ2 plays a crucial role in regulating MM cell proliferation and lipid peroxidation (LPO)...
March 10, 2024: British Journal of Haematology
https://read.qxmd.com/read/38454813/selinexor-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma
#16
REVIEW
Anum Babar, Maham Babar, Hina Zubair, Arzu Shahid, Sana Rafique, Maimona Bano, Madeeha Subhan Waleed, Maimoona Khan, Arslan Inayat, Danish Safi
OBJECTIVE: Multiple myeloma cells resist standard therapies due to overexpression of the transport protein, exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein in these cells. DATA SOURCE: A comprehensive search was done, and data showing the efficacy and safety of selinexor in relapsed/refractory multiple myeloma was collected using PubMed, Google Scholar, and clincialtrials.gov. DATA SUMMARY: Results from the clinical trials STORM, BOSTON, and STOMP were included...
March 8, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38454765/daptomycin-inhibits-multiple-myeloma-progression-through-downregulating-the-expression-of-rps19
#17
JOURNAL ARTICLE
Yijun Zhuang, Yin Zhang, Caiyun Chen, Jincheng Chen, Qiuxia Xu, Peihong Wang
OBJECTIVES: This study aimed to explore new therapeutic drugs for multiple myeloma (MM). MM is a common plasma cell malignant proliferative disease, accounting for 15% of hematological malignancies. The role of daptomycin (DAP), a potential anti-tumor drug, remains unclear in MM. In the present research, we investigated the anticancer effect of DAP in MM cell line RPMI 8226. METHODS: RPMI 8226 cells were treated with DAP (20 μM, 40 μM, and 80 μM) with 20 nM bortezomib (BZ) as a positive control...
March 6, 2024: Combinatorial Chemistry & High Throughput Screening
https://read.qxmd.com/read/38450304/complete-blood-and-urine-paraprotein-tests-as-response-assessments-in-multiple-myeloma-patients-treated-with-bortezomib-cyclophosphamide-and-dexamethasone
#18
JOURNAL ARTICLE
Xialu Lan, Fujing Zhang, Chen Yang, Wei Su, Jianhua Du, Shuangjiao Liu, Miao Chen, Bing Han, Daobin Zhou, Junling Zhuang
BACKGROUND: This study assessed the effect of standardized efficacy markers on prognosis in patients with newly diagnosed multiple myeloma (MM) during the induction phase of treatment with bortezomib, cyclophosphamide, and dexamethasone (BCD). METHODS: We retrospectively analyzed clinical data in 197 newly diagnosed MM patients treated with BCD as front-line regimen at Peking Union Medical College Hospital from January 1, 2013 to December 31, 2018. RESULTS: There were 107 patients with International Staging System (ISS) III and 51 with paraprotein of light chain...
March 2024: Chronic Diseases and Translational Medicine
https://read.qxmd.com/read/38448720/cost-effectiveness-of-novel-agent-regimens-for-transplant-eligible-newly-diagnosed-multiple-myeloma-patients-in-india
#19
JOURNAL ARTICLE
Jyoti Dixit, Pankaj Malhotra, Nikita Mehra, Anisha Mathew, Lalit Kumar, Ashish Singh, Nidhi Gupta, Manjunath Nookala Krishnamurthy, Partha Sarathi Roy, Amal Chandra Kataki, Sudeep Gupta, Shankar Prinja
BACKGROUND: Survival outcomes for multiple myeloma have improved dramatically since the introduction of novel therapeutic agents. While these drugs are highly effective in improving survival outcomes and quality of life in patients with multiple myeloma, they come at a significant cost. We assessed the cost-effectiveness of bortezomib-based triplet or quadruplet drug regimens in isolation and followed by autologous hematopoietic stem cell transplantation (AHSCT) for the treatment of newly diagnosed multiple myeloma (NDMM) in the Indian context...
March 7, 2024: Applied Health Economics and Health Policy
https://read.qxmd.com/read/38441437/gz17-6-02-interacts-with-proteasome-inhibitors-to-kill-multiple-myeloma-cells
#20
JOURNAL ARTICLE
Laurence Booth, Jane L Roberts, Cameron West, Paul Dent
GZ17-6.02, a synthetically manufactured compound containing isovanillin, harmine and curcumin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with a recommended phase 2 dose (RP2D) of 375 mg PO BID. GZ17-6.02 was more efficacious as a single agent at killing multiple myeloma cells than had previously been observed in solid tumor cell types. GZ17-6.02 interacted with proteasome inhibitors in a greater than additive fashion to kill myeloma cells and alone it killed inhibitor-resistant cells to a similar extent...
March 5, 2024: Oncotarget
keyword
keyword
108668
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.